UiPath (NYSE:PATH) Trading Down 1.5%

UiPath Inc. (NYSE:PATH - Get Free Report) traded down 1.5% on Wednesday . The stock traded as low as $19.59 and last traded at $19.71. 1,084,585 shares changed hands during mid-day trading, a decline of 87% from the average session volume of 8,297,682 shares. The stock had previously closed at $20.02.

Analyst Ratings Changes

A number of brokerages have weighed in on PATH. Canaccord Genuity Group lifted their price target on shares of UiPath from $27.00 to $30.00 and gave the company a "buy" rating in a research report on Friday, March 15th. Mizuho boosted their price target on UiPath from $22.00 to $25.00 and gave the stock a "neutral" rating in a research note on Thursday, March 14th. Royal Bank of Canada restated a "sector perform" rating and set a $29.00 price objective on shares of UiPath in a report on Monday, April 1st. DA Davidson increased their target price on UiPath from $20.00 to $24.00 and gave the company a "neutral" rating in a research note on Thursday, March 14th. Finally, Scotiabank lifted their price target on shares of UiPath from $29.00 to $30.00 and gave the stock a "sector perform" rating in a research note on Thursday, March 14th. Nine research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $27.41.

UiPath Trading Down 0.6 %

The company has a market capitalization of $11.32 billion, a price-to-earnings ratio of -117.06 and a beta of 1.01. The firm has a 50-day moving average price of $21.60 and a 200-day moving average price of $21.78.

UiPath (NYSE:PATH - Get Free Report) last posted its quarterly earnings data on Wednesday, March 13th. The healthcare company reported $0.06 earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.10. UiPath had a negative net margin of 6.87% and a negative return on equity of 3.29%. The company had revenue of $405.25 million during the quarter, compared to analyst estimates of $383.32 million. Equities research analysts predict that UiPath Inc. will post -0.04 EPS for the current fiscal year.

Insider Buying and Selling

In other UiPath news, CFO Ashim Gupta sold 40,000 shares of the business's stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $21.66, for a total transaction of $866,400.00. Following the sale, the chief financial officer now owns 660,762 shares in the company, valued at approximately $14,312,104.92. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 31.03% of the company's stock.

Institutional Trading of UiPath

Several large investors have recently added to or reduced their stakes in the company. Xponance Inc. raised its position in UiPath by 3.9% during the third quarter. Xponance Inc. now owns 44,846 shares of the healthcare company's stock valued at $767,000 after buying an additional 1,694 shares during the period. Raymond James & Associates increased its holdings in shares of UiPath by 51.0% in the 3rd quarter. Raymond James & Associates now owns 89,534 shares of the healthcare company's stock valued at $1,532,000 after purchasing an additional 30,244 shares during the period. Bank of New York Mellon Corp lifted its position in shares of UiPath by 0.6% in the third quarter. Bank of New York Mellon Corp now owns 2,385,317 shares of the healthcare company's stock worth $40,813,000 after purchasing an additional 15,334 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of UiPath by 27.7% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 94,499 shares of the healthcare company's stock worth $1,617,000 after purchasing an additional 20,491 shares during the period. Finally, Mackenzie Financial Corp purchased a new position in UiPath during the third quarter valued at approximately $2,359,000. 62.50% of the stock is owned by institutional investors and hedge funds.

About UiPath

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.